ES2155601T3 - Compuestos de benzolactama sustituidos como antagonistas de la sustancia p. - Google Patents
Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.Info
- Publication number
- ES2155601T3 ES2155601T3 ES96911079T ES96911079T ES2155601T3 ES 2155601 T3 ES2155601 T3 ES 2155601T3 ES 96911079 T ES96911079 T ES 96911079T ES 96911079 T ES96911079 T ES 96911079T ES 2155601 T3 ES2155601 T3 ES 2155601T3
- Authority
- ES
- Spain
- Prior art keywords
- substance
- subgonist
- benzolactama
- compounds substituted
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Abstract
ESTA INVENCION PROPORCIONA UN COMPUESTO DE FORMULA GENERAL (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN EL QUE: W ES UN METILENO, ETILENO, PROPILENO, VINILENO, 1}, R SUP,2} Y R SUP,3} SON INDEPENDIENTEMENTE HIDROGENO, ALQUILO C SUB,1} QUILO C SUB,1} METILENO, AMBOS R SUP,2} Y R SUP,3} NO SON HIDROGENO; X ES HALO, ALCOXI C SUB,1} LO C SUB,1} Y ES IMINO O OXI; Q ES OXIGENO O AZUFRE; Y T ES (2S,3S) FENILMETILQUINUCLIDIN 3 ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES INFLAMATORIAS, EMESIS, INCONTINENCIA URINARIA, DOLOR, MIGRAÑA, ANGIOGENESIS O SIMILARES EN UN MAMIFERO, ESPECIALMENTE SERES HUMANOS. SE DESCUBREN ASIMISMO INTERMEDIARIOS DE LOS COMPUESTOS ANTERIORES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9501359 | 1995-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2155601T3 true ES2155601T3 (es) | 2001-05-16 |
Family
ID=14126073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96911079T Expired - Lifetime ES2155601T3 (es) | 1995-07-07 | 1996-05-09 | Compuestos de benzolactama sustituidos como antagonistas de la sustancia p. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6180647B1 (es) |
EP (1) | EP0840732B1 (es) |
JP (1) | JP3042894B2 (es) |
AT (1) | ATE199552T1 (es) |
CA (1) | CA2226292C (es) |
DE (1) | DE69612003T2 (es) |
DK (1) | DK0840732T3 (es) |
ES (1) | ES2155601T3 (es) |
GR (1) | GR3035774T3 (es) |
MX (1) | MX9800187A (es) |
WO (1) | WO1997003066A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
TW436483B (en) * | 1997-08-19 | 2001-05-28 | Otsuka Pharma Co Ltd | Carbostyril derivatives, process for their preparation and pharmaceutical composition or cosmetic composition for inhibiting skin erythema and/or skin pigmentation |
TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
IL145945A0 (en) * | 1999-05-06 | 2002-07-25 | Pfizer Prod Inc | Substituted benzolactam compounds |
RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
HUP0201443A3 (en) * | 1999-05-21 | 2005-09-28 | Pfizer Prod Inc | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives and pharmaceutical compositions containing them |
PT1095939E (pt) * | 1999-10-18 | 2004-04-30 | Pfizer Prod Inc | Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo |
JP2001172178A (ja) * | 1999-10-25 | 2001-06-26 | Pfizer Prod Inc | 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン |
US7119207B2 (en) | 2000-04-10 | 2006-10-10 | Pfizer Inc | Benzoamide piperidine containing compounds and related compounds |
AP2002002647A0 (en) * | 2000-04-10 | 2002-12-31 | Pfizer Prod Inc | Benzoamide piperidine compounds as substance p antagonists |
US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
GB0108982D0 (en) | 2001-04-10 | 2001-05-30 | Merck Sharp & Dohme | Therapeutic agents |
NZ537301A (en) * | 2002-06-07 | 2006-06-30 | Cortical Pty Ltd | Therapeutic molecules and methods-1 |
WO2004036461A2 (en) * | 2002-10-14 | 2004-04-29 | Battelle Memorial Institute | Information reservoir |
US7514466B2 (en) | 2004-04-27 | 2009-04-07 | Wyeth | Purification of progesterone receptor modulators |
NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
AU2008204380B2 (en) | 2007-01-10 | 2013-08-15 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US20090197878A1 (en) * | 2008-02-01 | 2009-08-06 | Wyeth | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR |
JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
NZ596104A (en) | 2009-05-12 | 2014-01-31 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
KR20120023072A (ko) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | (S)-7-(〔1,2,4〕트리아졸〔1,5-a〕피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도 |
BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
JP6043285B2 (ja) | 2010-08-02 | 2016-12-14 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害 |
HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US20140045847A1 (en) | 2011-04-21 | 2014-02-13 | Piramal Enterprises Limited | Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
BR112015012295A8 (pt) | 2012-11-28 | 2023-03-14 | Merck Sharp & Dohme | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680283A (en) | 1984-09-26 | 1987-07-14 | Merck & Co., Inc. | Analogs of substance P and eledoisin |
MX18467A (es) | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
WO1994013663A1 (en) * | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
-
1996
- 1996-05-09 WO PCT/IB1996/000434 patent/WO1997003066A1/en active IP Right Grant
- 1996-05-09 DK DK96911079T patent/DK0840732T3/da active
- 1996-05-09 ES ES96911079T patent/ES2155601T3/es not_active Expired - Lifetime
- 1996-05-09 CA CA002226292A patent/CA2226292C/en not_active Expired - Fee Related
- 1996-05-09 AT AT96911079T patent/ATE199552T1/de not_active IP Right Cessation
- 1996-05-09 EP EP96911079A patent/EP0840732B1/en not_active Expired - Lifetime
- 1996-05-09 US US08/983,004 patent/US6180647B1/en not_active Expired - Fee Related
- 1996-05-09 JP JP9505628A patent/JP3042894B2/ja not_active Expired - Fee Related
- 1996-05-09 MX MX9800187A patent/MX9800187A/es not_active IP Right Cessation
- 1996-05-09 DE DE69612003T patent/DE69612003T2/de not_active Expired - Fee Related
-
2001
- 2001-04-20 GR GR20010400624T patent/GR3035774T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK0840732T3 (da) | 2001-04-17 |
MX9800187A (es) | 1998-05-31 |
ATE199552T1 (de) | 2001-03-15 |
JPH11502861A (ja) | 1999-03-09 |
US6180647B1 (en) | 2001-01-30 |
EP0840732B1 (en) | 2001-03-07 |
DE69612003D1 (de) | 2001-04-12 |
CA2226292C (en) | 2001-12-11 |
WO1997003066A1 (en) | 1997-01-30 |
GR3035774T3 (en) | 2001-07-31 |
CA2226292A1 (en) | 1997-01-30 |
EP0840732A1 (en) | 1998-05-13 |
JP3042894B2 (ja) | 2000-05-22 |
DE69612003T2 (de) | 2001-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2155601T3 (es) | Compuestos de benzolactama sustituidos como antagonistas de la sustancia p. | |
ATE244234T1 (de) | Substituierte imidazole zur behandlung von entzündlichen krankheiten | |
EA199700061A1 (ru) | Способ получения силденафила | |
MX9302906A (es) | Derivados de mercaptoacetilamida novedosos utiles como inhibidores de la encefalinasa. | |
PT1140944E (pt) | Derivados de epotilona e sua utilizacao como agentes antitumorais | |
EA199800667A1 (ru) | Новые фенантридины | |
EA200300566A1 (ru) | Применение cci-779 в качестве противоопухолевого средства | |
DE69732868D1 (de) | Mittel gegen Juckreiz | |
EA200000098A1 (ru) | 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y | |
PT1163208E (pt) | Inibidores de caspase e as suas utilizacoes | |
ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
MX9205678A (es) | Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa. | |
PT971922E (pt) | Compostos de tetra-hidropirido | |
ATE386742T1 (de) | Imidazonaphthyridine | |
SE9801494D0 (sv) | Novel use | |
ES2139669T3 (es) | Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa. | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ES2182035T3 (es) | Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa. | |
ECSP003590A (es) | Compuestos calcioliticos | |
FI980091A0 (fi) | Menetelmä ylijäämäaktiivilietteen käsittelemiseksi | |
EA199900174A1 (ru) | Способ лечения биполярного расстройства | |
NO912985L (no) | Forbedret system for transdermal applikasjon av farmasoeytisk aktive forbindelser ved regulert ph. | |
ATE204167T1 (de) | Antikonvulsive derivate zur behandlung von psoriasis | |
NO984198D0 (no) | Fremgangsmåte for behandling av aggresjon | |
EA200001105A1 (ru) | 10-камфорсульфонат пароксетина для лечения нарушений цнс |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 840732 Country of ref document: ES |